Supplement

Text Preparation

Documents were prepared for analysis following Centres for Medicare and Medicaid Services guidelines (2010) prior to using readability calculators(1). Incomplete sentences were removed, with full stops added to the end of any headings and complete sentence bullet points. URLs were replaced with the word “website’. Midsentence full stops e.g. “U.K.” were removed. In addition, text based tables using characters, most commonly ‘x’ to indicate trial interventions at different time points were removed.

Excluded PIS/ICFs.

Trial Name	Document date	Document Version	Sponsor	Study Design	Study Phase	Exclusion Reason
ABRA	06/03/2023	5.0	University of Oxford (AstraZeneca Unrestricted Grant)	Randomised, Parallel Assignment, Double blind	II	Non-COVID study Document outside screening period
STARR 2	15/06/2017	1.0	University of Oxford	Randomised, Parallel Assignment, Quadruple blind	IV	Non-COVID study Document outside screening period
STOIC	13/05/2020	1.0	University of Oxford	Randomised, Parallel Assignment, Open label	II	Outpatient clinical setting

Trial Summary information

Trial Name	Document date	Document Version	Sponsor	Study Design	Study Phase	Recruitment target	Intervention (Route of delivery)	Additional notes
RECOVERY	17/03/2020	1.4	Academic	Randomised,	III	50000	Lopinavir-	Translations

			(University of Oxford, Oxford)	Factorial assignment, Open label	(Platform)		Ritonavir (oral) Interferon (inhaled) Dexamethasone (Intavenous/Oral)	available.
REMAP-CAP	09/04/2020	1.3	Academic (University Medical Centre, Utrecht)	Randomised, Adaptive Bayesian Platform Trial evaluating multiple interventions in multiple domains. Open Label.	III (Platform)	10000	Multiple (Intravenous, Oral)	6 potential interventions, run concurrently based on clinical factors.
TACTIC-E	03/06/2020	1.1	Academic (Cambridge University Hospitals NHS Trust, Cambridge)	Randomised, Parallel assignment, Open label	II/III (Platform)	1407	EDP1815 (oral) Dapagliflozen (oral) Ambrisentan (oral)	Part A / Part B format
TACTIC-R	04/05/2020	1.2	Academic (Cambridge University Hospitals NHS Trust, Cambridge)	Randomised, Parallel assignment, Open label	III (Platform)	1167	Ravulizumab (Intravenous) Baricitinib (oral)	Part A / Part B format
GS-US-540-5773	27/03/2020	3	Gilead	Randomised, Parallel Assignment, Open label	III	400	Remdesevir (Intravenous)	
RUXCOVID	23/04/2020	0	Novartis	Randomized, Double-blind, Placebo-controlled	III	402	Ruxolitinib (Oral)	Offered summary sheet.

ACCORD-2	30/04/2020	1.2	Academic (University of Southampton)	Adaptive Randomisation, Platform study, Open label.	II	1800	Bemcentinib (Oral)	Offered summary sheet.
COVASE	24/04/2020	2	Academic (University College London Hospitals NHS)	Randomised, parallel assignment, open-label.	II	50	Dornase Alpha (nebulised)	Offered summary sheet.
ILEAD-7	06/05/2020	3	Revimmune	Randomised, Placebo, Quadruple-Blind.	II	48	Interleukin-7 (Intramuscular)	UK cohort of international study.
OSCAR GSK	01/05/2020	1	GlaxoSmithKline	Randomised, Placebo, Double-Blind.	II	800	Otilimab (Intravenous)	Offered summary sheet.
SPRINTER	26/10/2020	1	Synairgen Research Ltd.	Randomised, Double-Blind, Parallel Assignment.	III	610	SNG001 (Inhaled)	
SYNAIRGEN SG016	13/03/2020	2	Synairgen Research Ltd.	Randomised, Quadruple-blind Parallel Assignment.	II	220	SNG001 (Inhaled)	
Theravance 0188	18/05/2020	3	Theravance Biopharma	Randomised, Placebo, Triple-Blind.	II	159	TD-0903 (inhaled)	

Page totals & Subsection Analysis

Trial	Total Page Count		Privacy and Information Governance section		Benefits section		Risks section	
	PIS	ICF	Reading time (mins, 240	Words	Reading time (mins, 240 wpm)	Words	Reading time (mins, 240 wpm)	Words

			wpm)					
Phase III Platform trials								
RECOVERY	2	2	72	0.3	42	0.2	96	0.4
REMAP-CAP	8	2	661	2.8	133	0.6	328	1.4
TACTIC-E	13	3	517	2.2	41	0.2	573	2.4
TACTIC-R	9	3	519	2.2	41	0.2	255	1.1
Phase III Commercial								
GS-US-540-5773	13	3	988	4.1	85	0.4	495	2.1
RUXCOVID	14	4	1159	4.8	40	0.2	1189	5.0
SPRINTER	12	2	490	2.0	133	0.6	636	2.7
Phase II Trials								
ACCORD-2	14	4	968	4.0	0	0	949	4.0
COVASE	5	2	355	1.5	41	0.2	297	1.2
ILEAD-7	10	2	331	1.4	101	0.4	287	1.2
OSCAR GSK	20	5	531	2.2	125	0.5	801	3.3
SYNAIRGEN SG016	15	3	709	3.0	48	0.2	668	2.8
Theravance 0188	10	2	469	2.0	41	0.2	517	2.2
Overall								
Median	12.5	3	519	2.2	48	0.2	517	2.2

Plain English Criteria

Trial Name	Average Sentence Length (words)	Text in passive tense (%)	Avoids Capitals	Bullet Points	Avoids Underlining
RECOVERY	20.5	45%	Yes	No	Yes
REMAP-CAP	18	37%	Yes	No	Yes
TACTIC-E	20.5	42%	Yes	Yes	No
TACTIC-R	20.1	43%	Yes	Yes	No
GS-US-540-5773	19.4	37%	No	Yes	No
RUXCOVID	18.5	35%	Yes	Yes	No
SPRINTER	20.4	38%	No	Yes	No
ACCORD-2	19.1	41%	Yes	Yes	No
ILEAD-7	20.6	22%	No	Yes	No

OSCAR GSK	16.3	33%	Yes	Yes	No
SYNAIRGEN SG016	18.9	40%	Yes	Yes	No
Theravance 0188	18	40%	No	Yes	No

1. Toolkit for Making Written Material Clear and Effective - Part 7 : Using readability formulas: A cautionary note [Internet]. U.S. Department of Health and Human Services Centers for Medicare & Medicaid Services; 2010. Available from: https://montefioreeinstein.org/documents/ToolkitPart07.pdf